Semnur Pharmaceuticals, Inc. Operating Income Loss

Quick Answer

Semnur Pharmaceuticals, Inc. reported Operating Income Loss of -$160.42 million for the year ending 2025.

  • Semnur Pharmaceuticals, Inc. showed a decrease of -3,320.4% in Operating Income Loss from 2024 to 2025.
  • This data is from Semnur Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
  • XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 3 years of available data (2023 to 2025), Semnur Pharmaceuticals, Inc.'s Operating Income Loss has declined by 4,954.3%.
  • Historical annual values: Fiscal year 2025: -$160.42 million | Fiscal year 2024: -$4.69 million | Fiscal year 2023: -$3.17 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: